Evelo Biosciences Inc (EVLO) Shares Bought by Jane Street Group LLC

Jane Street Group LLC grew its holdings in shares of Evelo Biosciences Inc (NASDAQ:EVLO) by 12.3% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 19,785 shares of the company’s stock after buying an additional 2,174 shares during the period. Jane Street Group LLC owned 0.06% of Evelo Biosciences worth $257,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the company. American International Group Inc. increased its stake in shares of Evelo Biosciences by 155.2% during the fourth quarter. American International Group Inc. now owns 9,077 shares of the company’s stock valued at $118,000 after buying an additional 5,520 shares during the period. Geode Capital Management LLC increased its stake in shares of Evelo Biosciences by 74.8% during the fourth quarter. Geode Capital Management LLC now owns 90,197 shares of the company’s stock valued at $1,173,000 after buying an additional 38,596 shares during the period. Northern Trust Corp increased its stake in shares of Evelo Biosciences by 119.7% during the fourth quarter. Northern Trust Corp now owns 128,155 shares of the company’s stock valued at $1,667,000 after buying an additional 69,825 shares during the period. Citigroup Inc. increased its stake in shares of Evelo Biosciences by 164.8% during the fourth quarter. Citigroup Inc. now owns 3,900 shares of the company’s stock valued at $51,000 after buying an additional 2,427 shares during the period. Finally, Bank of New York Mellon Corp increased its stake in shares of Evelo Biosciences by 147.4% during the fourth quarter. Bank of New York Mellon Corp now owns 36,883 shares of the company’s stock valued at $480,000 after buying an additional 21,974 shares during the period. 85.05% of the stock is currently owned by hedge funds and other institutional investors.

EVLO has been the topic of several research analyst reports. ValuEngine cut Evelo Biosciences from a “buy” rating to a “hold” rating in a research note on Friday, December 21st. Chardan Capital initiated coverage on Evelo Biosciences in a research note on Tuesday, January 29th. They set a “neutral” rating and a $10.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Evelo Biosciences currently has an average rating of “Buy” and an average target price of $22.75.

Shares of EVLO stock opened at $8.15 on Wednesday. Evelo Biosciences Inc has a twelve month low of $6.51 and a twelve month high of $16.75. The company has a current ratio of 16.43, a quick ratio of 16.43 and a debt-to-equity ratio of 0.09.

Evelo Biosciences (NASDAQ:EVLO) last issued its quarterly earnings results on Thursday, February 14th. The company reported ($0.49) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.58) by $0.09. On average, equities research analysts predict that Evelo Biosciences Inc will post -2.48 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Evelo Biosciences Inc (EVLO) Shares Bought by Jane Street Group LLC” was first posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this story on another site, it was copied illegally and reposted in violation of international copyright and trademark laws. The correct version of this story can be viewed at https://www.com-unik.info/2019/04/17/evelo-biosciences-inc-evlo-shares-bought-by-jane-street-group-llc.html.

About Evelo Biosciences

Evelo Biosciences, Inc, a biotechnology company, focuses on the development of monocolonal microbials for the treatment of inflammatory diseases and cancer. It is involved in developing EDP1066 and EDP1815, which are in Phase 1b placebo-controlled dose-escalating safety and tolerability clinical study for the treatment of atopic dermatitis, asthma, psoriatic arthritis, rheumatoid arthritis, and inflammatory bowel diseases.

Recommended Story: What is a trade deficit?

Institutional Ownership by Quarter for Evelo Biosciences (NASDAQ:EVLO)

Receive News & Ratings for Evelo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evelo Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit